BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Quark Pharmaceuticals Inc. 

6501 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-402-4020 Fax: 510-402-4021


SEARCH JOBS










 Company News
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014 6:31:05 AM
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014 10:34:03 AM
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014 9:02:30 AM
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014 9:15:28 AM
Quark Pharmaceuticals Inc. And Suzhou Ribo Life Science Raise Nearly RMB 45 Million For Newly Established Chinese Joint Venture 1/7/2014 9:33:17 AM
Silence Therapeutics plc' Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. (PFE) to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5/3/2012 7:02:19 AM
Quark Pharmaceuticals Inc. Announces Phase 2a Study of PF--04523655 (PF-655) in Patients With Moderate and Advanced Open-Angle Glaucoma (OAG) 5/1/2012 10:16:34 AM
Quark Pharmaceuticals Inc. Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) 1/4/2012 10:33:13 AM
Regarding Announcement of Quark Pharmaceuticals Inc. 3/23/2011 10:18:42 AM
Silence Therapeutics plc Partner Quark Pharmaceuticals Inc. Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema 3/21/2011 9:38:51 AM
12345